Semaglutide (and Cagrilintide Context): A Six-Module Literature Course

This course summarises published research on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has been examined in rodent models, pharmacodynamic trials, large randomised programmes and safety reviews. Each of the six modules describes what researchers did, what they measured and what they reported, and closes with the limits of that evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician before considering any intervention. Nothing here describes a protocol, and no outcome described below should be read as a promise.

A note on naming: the phrase "cagrilintide semaglutide" refers to a co-formulation concept pairing an amylin analogue with semaglutide. The verified literature summarised on this page concerns semaglutide alone. Where cagrilintide is mentioned, it is only to state that the papers cited here did not study it.

Module 1: What Semaglutide Is and How It Has Been Studied

Definition and class

Semaglutide is a synthetic analogue of human GLP-1, an incretin hormone. A development history published in Frontiers in Endocrinology described how liraglutide and then semaglutide were engineered by acylating the peptide backbone with a fatty di-acid linker so that the molecule binds reversibly to plasma albumin, a design intended to slow clearance and support once-weekly administration (PMID 31031702). The same account described amino-acid substitutions that reduce degradation by dipeptidyl peptidase-4 (PMID 31031702).

Forms studied and study settings

A systematic review of clinical pharmacokinetics reported that semaglutide has been studied in both subcutaneous and oral formulations, the latter using an absorption enhancer to permit gastrointestinal uptake of a peptide (PMID 38952487). Research settings described in the literature span rodent models of body-weight regulation (PMID 32213703), short mechanistic crossover trials in people with obesity (PMID 28266779), pooled analyses of randomised trials in obesity without diabetes (PMID 36578889), and multi-year cardiovascular outcome cohorts (PMID 38740993). Narrative reviews have also summarised the obesity trial programme as a whole (PMID 36254579, PMID 34942372).

Limits of the evidence in Module 1

• Development histories describe design intent, not clinical performance; they are narrative sources rather than trials (PMID 31031702).
• The verified papers here do not characterise compounded, research-use-only or combination preparations, including cagrilintide-containing formulations.
• Trial populations were selected by entry criteria; characteristics of enrolled participants do not generalise automatically to other groups.

Module 2: Mechanism as Described in the Literature

The mechanism most often described is agonism at the GLP-1 receptor, a receptor expressed in the pancreas and in multiple regions of the central nervous system. A rodent study in JCI Insight reported that semaglutide lowered body weight through distributed neural pathways rather than a single discrete brain nucleus, with researchers mapping activity across several central populations rather than attributing the effect to one hypothalamic site (PMID 32213703).

In humans, a crossover trial in subjects with obesity examined appetite, ad libitum energy intake, control of eating and food preference during once-weekly semaglutide 1.0 mg over 12 weeks, and the study reported lower ad libitum energy intake and reduced body weight relative to placebo, alongside changes in appetite ratings and control-of-eating scores (PMID 28266779). Reviews of the obesity programme have summarised this appetite-mediated model as the leading explanation for weight change observed in trials (PMID 36254579, PMID 34942372).

Limits of the evidence in Module 2

• Rodent neuroanatomy does not transfer directly to humans; the rodent work reported mechanism in animals, not clinical benefit (PMID 32213703).
• The human mechanistic trial was short and crossover in design, measuring intake and appetite endpoints rather than long-term health outcomes (PMID 28266779).
• Mechanistic plausibility is not evidence of effect size in any individual.

Module 3: Reported Outcomes by Study

The table below groups the verified studies by model, endpoint and reported result. No row should be read as a prediction of outcome.

Narrative reviews have described the same programme from a clinical perspective, summarising semaglutide as an agent studied for chronic weight management and reporting the pattern of weight change across the randomised trials (PMID 36254579, PMID 34706925).

Limits of the evidence in Module 3

• Trial averages describe groups; individual responses within those trials varied and were not uniform (PMID 36578889).
• Long-term follow-up in the SELECT analysis occurred in a population selected for established cardiovascular disease without diabetes (PMID 38740993).
• Weight and intake endpoints are surrogate measures relative to hard clinical outcomes unless a trial measured those outcomes directly.
• Published trials used defined study products and supervised administration; they do not describe outcomes with unapproved or compounded material.

Module 4: Semaglutide Side Effects: What Studies Report

Adverse events are described here exactly as the cited papers framed them.

Gastrointestinal events

A dedicated safety review in Frontiers in Endocrinology reported that gastrointestinal events — nausea, vomiting, diarrhoea and constipation — were the most frequently observed adverse effects across the semaglutide trial programme, and were the most common reason for discontinuation (PMID 34305810). The meta-analysis of obesity trials without diabetes likewise reported a higher rate of gastrointestinal adverse events with semaglutide than with placebo (PMID 36578889).

Pancreatic, gallbladder and thyroid signals

The safety review discussed pancreatitis, gallbladder-related events and the rodent thyroid C-cell findings that underpin labelling warnings for GLP-1 receptor agonists (PMID 34305810). A clinical overview of the 2.4 mg weight-management product also described the boxed warning relating to thyroid C-cell tumours observed in rodents and contraindications tied to medullary thyroid carcinoma history (PMID 34706925).

Renal events

A 2024 report in Clinical Kidney Journal described semaglutide-associated kidney injury, with the authors discussing acute kidney injury arising in the context of gastrointestinal fluid losses and volume depletion (PMID 39258261). The broader safety review also addressed renal and other organ-system considerations within the trial data (PMID 34305810).

Other reported considerations

Reviews of the obesity literature reported that adverse events were generally described as most frequent during dose escalation and often gastrointestinal in character (PMID 36254579), and the safety review addressed retinopathy signals observed in diabetes trial data (PMID 34305810).

Limits of the evidence in Module 4

• Case reports and case series, such as the kidney-injury report, describe association and cannot establish causation (PMID 39258261).
• Rare events may be undetected in trials of limited size or duration, as the safety review itself noted (PMID 34305810).
• Trial safety data reflect monitored settings with eligibility screening and exclusion criteria.

Module 5: Pharmacokinetics Where Data Exist

A systematic review of clinical pharmacokinetics reported that semaglutide has a prolonged elimination half-life of approximately one week, consistent with once-weekly subcutaneous administration, and summarised absorption, distribution and clearance data across formulations and populations (PMID 38952487). That review also reported that the oral formulation relies on an absorption enhancer and that exposure differs between oral and subcutaneous routes (PMID 38952487).

The molecular basis for this extended exposure was described in the development history: albumin binding via the fatty di-acid side chain, together with DPP-4-resistant substitutions, was reported as the design strategy that extended circulating half-life relative to native GLP-1 (PMID 31031702). Because steady state is reached only after repeated weekly administration, the pharmacokinetic review discussed accumulation over several weeks (PMID 38952487).

Limits of the evidence in Module 5

• Pharmacokinetic parameters are population averages; the review itself reported variability across subgroups and formulations (PMID 38952487).
• Published PK data derive from characterised, regulated study product; they do not describe unverified material of unknown purity or concentration.
• Exposure does not map linearly onto effect or onto adverse-event risk.

Module 6: Regulatory Status

Approved products

Semaglutide is marketed in approved formulations for type 2 diabetes and, separately, for chronic weight management. A review of the weight-management product described its approval at the 2.4 mg once-weekly dose for chronic weight management in adults meeting body-mass-index criteria, together with its labelling and boxed warning (PMID 34706925). Clinical reviews have summarised both subcutaneous and oral approved presentations within the wider treatment landscape (PMID 36254579, PMID 38952487).

Research-use-only material

Peptide material labelled "research use only" (RUO) is, by that label, not approved for human administration and is not subject to the manufacturing, identity and sterility standards that apply to approved injectable drug products. RUO labelling is a statement about permitted use, not a statement about quality, and no verified study cited on this page evaluated RUO-labelled semaglutide.

Compounding

Compounded semaglutide preparations became widely discussed during periods when approved products were listed in shortage, because United States compounding law permits certain preparations of a drug in shortage under defined conditions. Compounded preparations are not FDA-approved products: they are not reviewed for safety, efficacy or manufacturing quality in the way an approved product is, and salt forms of an active ingredient are not interchangeable with the approved base. Combination concepts such as cagrilintide with semaglutide are investigational in nature and are not represented among the approved products described in the sources cited here.

This section states regulatory facts for education and is not legal advice; regulations change and vary by jurisdiction.

Limits of the evidence in Module 6

• Approval status changes over time and differs by country; published reviews capture the position at the time of writing (PMID 34706925).
• The verified literature describes approved study product only; no cited paper characterises compounded material.

What the Studies Did Not Test

• Cagrilintide co-formulation. None of the verified papers cited here evaluated cagrilintide, alone or combined with semaglutide; statements about such combinations cannot be supported by this evidence set.
• Non-approved sources. No cited study assessed the identity, purity or potency of compounded or research-use-only material.
• Healthy-population use. Trials enrolled defined clinical populations — obesity, overweight with cardiovascular disease, or heart failure with preserved ejection fraction (PMID 38740993, PMID 40886075) — not people outside those criteria.
• Indefinite duration. The longest verified follow-up described roughly four years of treatment, and researchers reported outcomes only within that window (PMID 38740993).
• Unsupervised administration. Trials involved clinician oversight, escalation schedules and monitoring; the literature does not describe outcomes without that structure (PMID 34305810).
• Stacking or co-administration with other peptides. No cited study examined such combinations.

Course Summary

Across six modules, the verified literature described semaglutide as an albumin-binding GLP-1 analogue (PMID 31031702) acting through distributed central pathways in rodents (PMID 32213703) and appetite-related mechanisms in humans (PMID 28266779), with pooled and long-term trial data reporting weight reduction versus placebo (PMID 36578889, PMID 38740993), predominantly gastrointestinal adverse events plus reported pancreatic, gallbladder, thyroid and renal considerations (PMID 34305810, PMID 39258261), and a half-life of about one week (PMID 38952487). Readers with clinical questions should direct them to a licensed physician.

References

• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity (Diabetes, Obesity & Metabolism, 2017)
• Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (Nature Medicine, 2024)
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (JAMA, 2025)
• Safety of Semaglutide (Frontiers in Endocrinology, 2021)
• Semaglutide-associated kidney injury (Clinical Kidney Journal, 2024)
• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
• Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
• Semaglutide for the treatment of overweight and obesity: A review (Diabetes, Obesity & Metabolism, 2023)
• Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)